311 related articles for article (PubMed ID: 27506281)
1. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
2. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization, and cytotoxicity of dinuclear platinum-bisphosphonate complexes to be used as prodrugs in the local treatment of bone tumours.
Margiotta N; Ostuni R; Gandin V; Marzano C; Piccinonna S; Natile G
Dalton Trans; 2009 Dec; (48):10904-13. PubMed ID: 20023921
[TBL] [Abstract][Full Text] [Related]
4. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Specific, Intracellular, Reductive Activation of Anticancer Pt
Reshetnikov V; Daum S; Mokhir A
Chemistry; 2017 Apr; 23(24):5678-5681. PubMed ID: 28319647
[TBL] [Abstract][Full Text] [Related]
6. A Multi-action and Multi-target Ru
Karges J; Yempala T; Tharaud M; Gibson D; Gasser G
Angew Chem Int Ed Engl; 2020 Apr; 59(18):7069-7075. PubMed ID: 32017379
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.
Ravera M; Gabano E; Zanellato I; Fregonese F; Pelosi G; Platts JA; Osella D
Dalton Trans; 2016 Mar; 45(12):5300-9. PubMed ID: 26903367
[TBL] [Abstract][Full Text] [Related]
8. Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity.
Tripathy SK; De U; Dehury N; Pal S; Kim HS; Patra S
Dalton Trans; 2014 Oct; 43(39):14546-9. PubMed ID: 25160655
[TBL] [Abstract][Full Text] [Related]
9. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.
Yap SQ; Chin CF; Hong Thng AH; Pang YY; Ho HK; Ang WH
ChemMedChem; 2017 Feb; 12(4):300-311. PubMed ID: 28028938
[TBL] [Abstract][Full Text] [Related]
10. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
11. Organoruthenium Complexes with C^N Ligands are Highly Potent Cytotoxic Agents that Act by a New Mechanism of Action.
Novohradsky V; Yellol J; Stuchlikova O; Santana MD; Kostrhunova H; Yellol G; Kasparkova J; Bautista D; Ruiz J; Brabec V
Chemistry; 2017 Nov; 23(61):15294-15299. PubMed ID: 28922506
[TBL] [Abstract][Full Text] [Related]
12. RNA binding and inhibition of primer extension by a Ru(III)/Pt(II) metal complex.
Jain SS; Anderson CM; DiRienzo F; Taylor IR; Jain K; Guha S; Hoque N
Chem Commun (Camb); 2013 Jun; 49(44):5031-3. PubMed ID: 23615723
[TBL] [Abstract][Full Text] [Related]
13. Rational design of dicarboxylato platinum(II) complexes with purine-mimetic ligands as novel anticancer agents.
Hoffmann K; Wiśniewska J; Wojtczak A; Sitkowski J; Denslow A; Wietrzyk J; Jakubowski M; Łakomska I
J Inorg Biochem; 2017 Jul; 172():34-45. PubMed ID: 28477537
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents.
Camm KD; El-Sokkary A; Gott AL; Stockley PG; Belyaeva T; McGowan PC
Dalton Trans; 2009 Dec; (48):10914-25. PubMed ID: 20023922
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative activity of dmoPTA-Ru(II) complexes against human solid tumor cells.
Ríos-Luci C; León LG; Mena-Cruz A; Pérez-Roth E; Lorenzo-Luis P; Romerosa A; Padrón JM
Bioorg Med Chem Lett; 2011 Aug; 21(15):4568-71. PubMed ID: 21719285
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
17. trans,cis,cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer.
Gandin V; Marzano C; Pelosi G; Ravera M; Gabano E; Osella D
ChemMedChem; 2014 Jun; 9(6):1299-305. PubMed ID: 24715720
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.
Jagodinsky JC; Sulima A; Cao Y; Poprawski JE; Blackman BN; Lloyd JR; Swenson RE; Gottesman MM; Hall MD
J Biol Inorg Chem; 2015 Oct; 20(7):1081-95. PubMed ID: 26323351
[TBL] [Abstract][Full Text] [Related]
19. Enhanced cancer cell killing of a Pt(IV) prodrug promoted by outer-sphere coordination with polyethyleneimines.
Garaikoetxea Arguinzoniz A; Gómez Blanco N; Ansorena Legarra P; Mareque-Rivas JC
Dalton Trans; 2015 Apr; 44(16):7135-8. PubMed ID: 25812853
[TBL] [Abstract][Full Text] [Related]
20. Metal-based anticancer chemotherapeutic agents.
Muhammad N; Guo Z
Curr Opin Chem Biol; 2014 Apr; 19():144-53. PubMed ID: 24608084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
